Outer retinal transduction by AAV2-7m8 following intravitreal injection in a sheep model of CNGA3 achromatopsia
The DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.
Abstract
Sheep carrying a mutated CNGA3 gene exhibit diminished cone function and provide a naturally occurring large animal model of achromatopsia. Subretinal injection of a vector carrying the CNGA3 transgene resulted in long-term recovery of cone function and photopic vision in these sheep. Research is underway to develop efficacious vectors that would enable safer transgene delivery, while avoiding potential drawbacks of subretinal injections. The current study evaluated two modified vectors, adeno-associated virus 2-7m8 (AAV2-7m8) and AAV9-7m8. Intravitreal injection of AAV2-7m8 carrying enhanced green fluorescent protein under a cone-specific promoter resulted in moderate photoreceptor transduction in wild-type sheep, whereas peripheral subretinal delivery of AAV9-7m8 resulted in the radial spread of the vector beyond the point of deposition. Intravitreal injection of AAV2-7m8 carrying human CNGA3 in mutant sheep resulted in mild photoreceptor transduction, but did not lead to the clinical rescue of photopic vision, while day-blind sheep treated with a subretinal injection exhibited functional recovery of photopic vision. Transgene messenger RNA levels in retinas of intravitreally treated eyes amounted to 4-23% of the endogenous CNGA3 levels, indicating that expression levels >23% are needed to achieve clinical rescue. Overall, our results indicate intravitreal injections of AAV2.7m8 transduce ovine photoreceptors, but not with sufficient efficacy to achieve clinical rescue in CNGA3 mutant sheep.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, AAV2 or AAV2 variants are often used to for intravitreal injection62–64, while AAV8 is commonly used for subretinal injection65,66.”
From An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species (2024) · cites this paper as [63]
Citations
Cites
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“Indeed, the first gene augmentation therapy approved for marketing (LuxturnaTM) involves SR delivery of a viral vector targeting the RPE for the treatment of Leber’s congenital amaurosis, [21, 22] and many other studies and clinical trials are underway utilizing this delivery method [4].”
MethodHauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954 · cited 1×
“Retinal detachment, although temporary, jeopardizes photoreceptor integrity and could result in substantial postoperative complications such as the formation of macular holes, macular detachment, or retinal thinning [23, 24].”
BackgroundLong-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743 · cited 1×
“Indeed, the first gene augmentation therapy approved for marketing (LuxturnaTM) involves SR delivery of a viral vector targeting the RPE for the treatment of Leber’s congenital amaurosis, [21, 22] and many other studies and clinical trials are underway utilizing this delivery method [4].”
MethodDalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734 · cited 13×
“Moreover, only a small area of the retina around the subretinal bleb can be treated, whereas most IRD’s exhibit a panretinal phenotype.”
BackgroundInfluentialSelf-citationPartial recovery of visual function in a blind patient after optogenetic therapy
Sahel, J.-A., Boulanger-Scemama, E., Pagot, C., Arleo, A., Galluppi, F., Martel, J. N., Esposti, S. D., Delaux, A., de Saint Aubert, J.-B., de Montleau, C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01351-4 · Cited by 700 · cited 1×
“AAV2-7m8 to target the inner retina of retinitis pigmentosa patients (NCT03326336) [53] with encouraging results [54].”
BackgroundSelf-citationAurnhammer, C., Haase, M., Muether, N., Hausl, M., Rauschhuber, C., Huber, I., Nitschko, H., Busch, U., Sing, A., Ehrhardt, A., et al. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2011.034 · Cited by 490 · cited 7×
“Cohort 2—efficacy trials: This cohort included seven day-blind, CNGA3 mutant sheep that were used to assess the efficacy of the most efficient vector found in the WT cohort, using maze testing, ERG, IHC, and PCR. Based on the results in WT sheep of cohort 1, nine eyes of eight CNGA3 mutant sheep were injected with AAV…”
MethodInfluentialAdeno-Associated Virus Vector Genomes Persist as Episomal Chromatin in Primate Muscle
Penaud-Budloo, M., Le Guiner, C., Nowrouzi, A., Toromanoff, A., Chérel, Y., Chenuaud, P., Schmidt, M., von Kalle, C., Rolling, F., Moullier, P., et al. (2008) · Journal of Virology · doi:10.1128/jvi.00649-08 · Cited by 317 · cited 1×
“While such high expression levels of an exogenous gene may seem unexpected, one should recall that rAAV vector genomes persist mostly in an episomal state [60] and therefore may be subjected to different genomic regulatory elements than the endogenous gene.”
BackgroundNovel properties of tyrosine-mutant AAV2 vectors in the mouse retina
Petrs-Silva, H., Dinculescu, A., Li, Q., Deng, W.-T., Pang, J.-J., Min, S.-H., Chiodo, V., Neeley, A. W., Govindasamy, L., Bennett, A., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.234 · Cited by 267 · cited 2×
“Two rationally designed vectors designed to evade proteasome degradation (AAV8-doubleY-F and AAV2-quadY-F+ V-T) [57, 58] were previously evaluated in our sheep, but were unsuccessful in achieving outer retinal transduction following IVT delivery [47].”
BackgroundGene therapy rescues cone function in congenital achromatopsia
Komáromy, A. M., Alexander, J. J., Rowlan, J. S., Garcia, M. M., Chiodo, V. A., Kaya, A., Tanaka, J. C., Acland, G. M., Hauswirth, W. W., & Aguirre, G. D. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq136 · Cited by 217 · cited 1×
“Proofof-concept trials in dogs [5, 6] and rodents [7] paved the way for clinical trials in patients affected by CNGB3 mutations, whereas clinical trials for CNGA3 achromatopsia patients were approved based on preliminary trials performed in mice [8] and our studies in CNGA3 mutant, day-blind sheep [9].”
BackgroundMacé, E., Caplette, R., Marre, O., Sengupta, A., Chaffiol, A., Barbe, P., Desrosiers, M., Bamberg, E., Sahel, J.-A., Picaud, S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.154 · Cited by 197 · cited 1×
“IVT injection of the AAV2-7m8 vector in a mouse model of Betten disease similarly resulted in bipolar cell transduction and rescue of photoreceptor function [38], and the vector was also used to target channelrhodopsin-2 to ON-bipolar cells leading to restoration of ON and OFF responses in retinas of blind mice [50].”
BackgroundSelf-citation
Cited by
AAV for Gene Therapy in Ocular Diseases: Progress and Prospects
He, X., Fu, Y., Ma, L., Yao, Y., Ge, S., Yang, Z. H., & Fan, X. (2023) · Research · doi:10.34133/research.0291 · Cited by 79
Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?
Ail, D., Malki, H., Zin, E. A., & Dalkara, D. (2023) · The Application of Clinical Genetics · doi:10.2147/tacg.s383453 · Cited by 40
Self-citationAn adeno-associated virus variant enabling efficient ocular-directed gene delivery across species
Luo, S., Jiang, H., Li, Q., Qin, Y., Yang, S., Li, J., Xu, L., Gou, Y., Zhang, Y., Liu, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48221-4 · Cited by 39
Adeno-associated virus therapies: Pioneering solutions for human genetic diseases
Liu, D., Tian, L., Liu, L., Che, X., Li, X., Liu, C., & Wu, G. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.09.003 · Cited by 32
Naturally-occurring myopia and loss of cone function in a sheep model of achromatopsia
Ross, M., Ofri, R., Aizenberg, I., Abu–Siam, M., Pe’er, O., Arad, D., Rosov, A., Gootwine, E., Dvir, H., Honig, H. H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76205-z · Cited by 13
Self-citation
Metadata
- Authors
- Ross, M., Obolensky, A., Averbukh, E., Desrosiers, M., Ezra-Elia, R., Honig, H., Yamin, E., Rosov, A., Dvir, H., Gootwine, E., Banin, E., Dalkara, D., & Ofri, R.
- Affiliations
- Hebrew University of Jerusalem (IL)
- Hadassah Medical Center (IL)
- Institut de la Vision (FR)
- Agricultural Research Organization (IL)
- Corresponding author
- Ofri, R.
- Venue
- Gene Therapy
- Published
- 2021-12-02
- Volume
- 29
- Issue
- 10-11
- Pages
- 624-635
- ISSN
- 0969-7128 (ISSN-L)
- 1476-5462
- OpenAlex
- W3215271512
- Cited by
- 13
- References
- 64
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 5 · 2023: 2
- FWCI
- 0.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Gene Therapy (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-18-IAHU-0001, ANR-10-LABX-0065)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- intravitreal injection, subretinal injection, phototransduction, sheep model, cone function, transgene expression levels
- MeSH terms
- Dependovirus, Animals, Color Vision Defects, Genetic Vectors, Humans, Retina, Sheep, Transduction, Genetic, Genetic Therapy, Cyclic Nucleotide-Gated Cation Channels, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Outer retinal transduction by AAV2-7m8 following intravitreal injection in a sheep model of CNGA3 achromatopsia. https://app.cochat.ai/papers/10.1038/s41434-021-00306-1
- The paper
- Ross, M., Obolensky, A., Averbukh, E., Desrosiers, M., Ezra-Elia, R., Honig, H., Yamin, E., Rosov, A., Dvir, H., Gootwine, E., Banin, E., Dalkara, D., & Ofri, R. (2022). Outer retinal transduction by AAV2-7m8 following intravitreal injection in a sheep model of CNGA3 achromatopsia. Gene Therapy. https://doi.org/10.1038/s41434-021-00306-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.